Mitragynine Reduces Chemotherapy-Induced Neuropathy with Sex-Dependent Potency

Why it matters

Mitragynine, kratom's primary alkaloid, significantly reduced chemotherapy-induced peripheral neuropathy in a mouse model, with males showing greater potency than females — findings with direct implications for individualized pain management in cancer survivors.

The big picture

Chemotherapy-induced peripheral neuropathy affects up to 100% of patients on platinum-based drugs with few effective treatments; this research positions mitragynine as a potential therapeutic candidate that acts through multiple pain-relief pathways shared with existing clinical treatments.

Key findings

• • Mitragynine dose-dependently attenuated oxaliplatin-induced mechanical hypersensitivity in both male and female mice
• • Males showed greater potency and efficacy at the highest dose (10 mg/kg) compared to females
• • Efficacy was mediated through mu-opioid, alpha-1, and alpha-2 adrenergic receptors — not beta-adrenergic receptors
• • Pharmacological mechanisms overlap with existing clinical neuropathic pain treatments (opioids and adrenergic agents)

What they say

Preclinical mouse study using oxaliplatin CIPN model; Temple University Lewis Katz School of Medicine, published in IBRO Neuroscience Reports 2022 (N = male and female C57BL/6J mice).

Bottom line

Mitragynine effectively reduces chemotherapy-induced nerve pain in mice, with sex-based differences in potency that could inform personalized cancer pain treatment strategies.